Bacil Pharma has approved a proposal to raise funds by way of a rights issue of equity shares for an aggregate amount of up to ₹50,00,00,000. The decision was taken during a board meeting held on July 9, 2026, aimed at bolstering the company's capital base. The rights issue will be conducted in accordance with the Companies Act, 2013, and SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, subject to necessary approvals.

To facilitate the issuance, the board approved an increase in the authorised share capital by ₹45,00,00,000, divided into 4,50,00,000 equity shares of ₹10 each. This will raise the total authorised share capital to ₹65,00,00,000 and necessitate the alteration of the capital clause of the Memorandum of Association, pending shareholder approval.

Rights Issue Committee and Appointments

The board constituted a Rights Issue Committee to oversee the process. The committee includes Chaitali Kalpataru Shah as Chairman, and Vivek Mukesh Yadav and Omprakash Pyarelal Sonar as members. Additionally, the board appointed M/s Purva Sharegistry (India) Private Limited as the Registrar, Axis Bank Limited as the Banker to the Issue, and Acuite Ratings & Research Limited as the Monitoring Agency.

Board Decisions

The meeting also saw the approval of resignations from Mr. Dinesh Chander Notiyal and Ms. Avani Savjibhai Godhaniya, both Independent Directors. Ms. Chaitali Kalpataru Shah and the Company Secretary were authorized to complete necessary filings and documentation for the rights issue.

Bacil Pharma has received approval from the Registrar of Companies, Central Registration Centre (CRC), for the name “Bacil Research & Development Private Limited” for its proposed wholly-owned subsidiary. The approval, dated July 6, 2026, grants the company the right to use the name for a period of 20 days, valid until July 26, 2026. This move marks a step forward in the company's expansion strategy through the establishment of a new subsidiary focused on research and development.

The name reservation was applied for on July 3, 2026, and subsequently approved by Charan Singh, Assistant Registrar of Companies. The approval letter explicitly states that the company cannot commence business or enter into any agreements until a Certificate of Registration is issued by the Registrar of Companies under the provisions of the Companies Act, 2013. The incorporation process is currently under progress, and the company intends to make necessary disclosures upon completion.

Regulatory Compliance and Validity

The approval is subject to specific conditions and timelines. The name availability is valid for 20 days from the date of approval, and the name may be withdrawn if found to be non-compliant with regulations at a later stage. The company must complete the incorporation process within this validity period to secure the name permanently.

The disclosure was made to the BSE Limited pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation was signed by Chaitali Kalpataru Shah, Director of Bacil Pharma, on July 7, 2026.

Key Details of the Name Approval

The company has assured that it will take all necessary steps to complete the incorporation and will inform the exchanges upon receipt of the Certificate of Incorporation.